efgartigimod alfa

Ligand id: 9777

Name: efgartigimod alfa

No information available.
Summary of Clinical Use
ARGX-113 has completed Phase 2 trial in patients with myasthenia gravis (MG), and will be evaluated in separate Phase 2 clinical trials for pemphigus vulgaris and primary immune thrombocytopenia. Click here to view ClinicalTrials.gov's registered ARGX-113 trials. ARGX-113 was granted FDA orphan drug designation for the treatment of MG in September 2017 [1].